As the U.S. stock market navigates the complexities of inflation and employment data, investors are increasingly attentive to economic indicators that influence Federal Reserve policies and interest rate decisions. Amidst this cautious environment, identifying undervalued stocks can provide opportunities for those looking to capitalize on potential market mispricings.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Click here to see the full list of 188 stocks from our Undervalued US Stocks Based On Cash Flows screener.

We'll examine a selection from our screener results.

Celsius Holdings

Overview: Celsius Holdings, Inc. is a company that develops, processes, markets, distributes, and sells functional energy drinks and liquid supplements across various international markets with a market cap of $7.11 billion.

Operations: The company's revenue comes from its non-alcoholic beverages segment, totaling $1.49 billion.

Estimated Discount To Fair Value: 19%

Celsius Holdings appears undervalued based on cash flows, trading at US$34.91, below its estimated fair value of US$43.1. Recent earnings show strong growth with Q2 sales reaching US$401.98 million and net income at US$79.78 million, reflecting significant year-over-year increases. While profit growth is projected at 16.7% annually—outpacing the broader U.S. market—revenue growth is anticipated to be slower than 20% per year but faster than the market average of 8.8%.

• The growth report we've compiled suggests that Celsius Holdings' future prospects could be on the up.
• Dive into the specifics of Celsius Holdings here with our thorough financial health report.

Alnylam Pharmaceuticals

Overview: Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in the discovery, development, and commercialization of novel therapeutics using ribonucleic acid interference technology, with a market cap of approximately $34.78 billion.

Operations: The company's revenue segment primarily comprises $2.34 billion from the discovery, development, and commercialization of RNAi therapeutics.

Estimated Discount To Fair Value: 46.6%

Alnylam Pharmaceuticals is trading at US$278.62, significantly below its estimated fair value of US$521.7, suggesting it may be undervalued based on cash flows. Recent earnings reveal substantial revenue growth to US$659.83 million for Q2 2024, with a narrowed net loss of US$16.89 million compared to the previous year. The company is expected to achieve profitability within three years, with forecasted revenue growth outpacing the broader U.S. market average at 19.3% annually.

• In light of our recent growth report, it seems possible that Alnylam Pharmaceuticals' financial performance will exceed current levels.
• Delve into the full analysis health report here for a deeper understanding of Alnylam Pharmaceuticals.

Corning

Overview: Corning Incorporated operates in the display technologies, optical communications, environmental technologies, specialty materials, and life sciences sectors both in the United States and internationally, with a market cap of approximately $39.99 billion.

Operations: The company's revenue segments include Display Technologies ($3.73 billion), Optical Communications ($3.86 billion), Environmental Technologies ($1.76 billion), Specialty Materials ($1.99 billion), and Life Sciences ($957 million).

Estimated Discount To Fair Value: 13.9%

Corning is trading at US$46.02, below its estimated fair value of US$53.44, indicating potential undervaluation based on cash flows. The company's earnings are projected to grow significantly at 28.3% annually, outpacing the broader U.S. market's growth rate. Despite high debt levels and a dividend not well covered by earnings or free cash flows, Corning's innovative product developments in semiconductor materials could enhance future revenue streams and support its valuation outlook.

• Our growth report here indicates Corning may be poised for an improving outlook.
• Click here to discover the nuances of Corning with our detailed financial health report.

Key Takeaways

• Dive into all 188 of the Undervalued US Stocks Based On Cash Flows we have identified here.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqCM:CELH NasdaqGS:ALNY and NYSE:GLW.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com